|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.30 - 4.35|
|52 Week Range||3.19 - 7.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK , January 3, 2018 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company announced today that Denis Corin , Chief Executive Officer, will present at the Biotech Showcase(™) ...
NEW YORK, Dec. 21, 2017 /PRNewswire/ -- Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide this year end update to its shareholders. The Company also ends the year with a clean balance sheet, having settled all outstanding debt and is poised for a very productive a catalyst-rich year in 2018. Strontium-89 is a U.S. Food and Drug Administration approved drug for pain palliation in bone metastases, primarily from breast, prostate and lung cancers.
Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today that all convertible notes and loans have been settled in full, including the $4 million of convertible notes that had been issued pursuant to a Securities Purchase Agreement dated November 29, 2016. The company ended its 2017 financial year with no outstanding loans or convertible debt. This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Dr. Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001.
Q BioMed Inc. (QBIO) congratulates our collaborative research partner and licensor, Mannin Research Inc., on receiving R&D funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to initiate work on a Tie2-activating biologic for the treatment of glaucoma. Q BioMed has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications. This new biologic would be an additional product to the Mannin Tie2 pipeline.
Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today that their funding partner Yorkville Advisors have agreed to extend the maturity date on the $2M balance of their convertible note by one year to November 30 2018. Dens Corin, CEO of QBioMed Inc. said, "Our relationship with Yorkville Advisors and their team has been very positive.
Q BioMed Inc. (QBIO), a biotechnology acceleration Company, announced today the launch of http://www.PainFreeCancer.com. In the body, Strontium-89 acts similar to calcium and is preferentially taken up in osteoblastic tissue selectively localizing in bone mineral. Strontium Chloride Sr89 Injection, USP can be used in combination with other therapeutic drugs.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder. "The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers that become non- or minimally verbal for the rest of their lives," said Denis Corin, CEO of Q BioMed. Sphaera Pharma will employ its proprietary and patented platform to produce a novel analog that aims to reduce or eliminate potential side effects and can reduce the amount of product a toddler needs to take on a daily basis.
Q BioMed Inc. (QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors provides the necessary capital to meet near term milestones and catalysts in its most advanced product portfolio assets, including the commercialization of Strontium Chloride 89, multiple IND enabling studies, CMC manufacturing and at least one IND filing.
NEW YORK , July 10, 2017 /PRNewswire/ -- Q BioMed Inc. (QBIO) will be featured on CEO Clips airing on Bloomberg Television July 10 through 14th . CEO Clips, profiles some of the most innovative publicly ...
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2017) - Darin Corin, CEO of Q BioMed, talks about the future plans for the company which includes a new drug application.If you cannot view the video above, please visit:http://www.b-tv.com/q-biomed-ceo-clip/Q BioMed Inc. is being featured on CBC's Documentary Channel July 10 -23, Monday through Friday, throughout the day and evenings. Q BioMed Inc.(OTCQB: QBIO) :Q BioMed Inc. is a biomedical acceleration and development company. We are dedicated ...
NEW YORK, NY / ACCESSWIRE / July 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued ...
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that Christopher Manuele will join the Strontium 89 Chloride commercialization team. Mr. Manuele is a results-oriented, innovative executive with thirty-five years of comprehensive US and International expertise in nuclear medicine and medical isotope production. Before his retirement in 2008, Mr. Manuele served as General Manager - Global Nuclear Medicine Supply Chain for GE Healthcare, and General Manager - Oncura, GE's global I-125 brachytherapy seeds business.
Q BioMed Inc. (QBIO), is very pleased to announce their entry into a final license agreement with The Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB). Under the agreement QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer. In animal models, the compound, called uttrocide B, was shown to be 10 times more cytotoxic to HepG2 liver cancer cells than the only drug currently on the market for the condition.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that it will be a featured presenter at the 6th Annual Marcum MicroCap Conference on Thursday, June 15, 2017 in New York City at the Grand Hyatt Hotel. The Company's presentation by Denis Corin, Q BioMed Inc. CEO, is scheduled to begin at 9:30a.m ET on Thursday June 15th in the Julliard Room. Since its launch in 2012, this event has become a nationally recognized forum for publicly traded companies with less than $500 million in market capitalization to network with fund managers and high net worth investors who focus on small cap equities.
Q BioMed Inc. (QBIO), and executives from its advanced technology partner Bio-Nucleonics Inc. will attend the upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting that is being held in Denver, Colorado June 10 - 14, 2017. The meeting provides an ideal location to meet with collaborators, vendors and partners working on the recently announced commercialization of Strontium-89 Chloride (Sr89). Sr89 Injection USP is a non-opioid analgesic indicated for the relief of bone pain in patients with painful skeletal cancer metastases.
Q BioMed Inc. (QBIO), is very pleased to announce that the company has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. Denis Corin, CEO of the Company said, "This is a major milestone in our short history. Approximately 70% of patients with advanced breast and prostate cancer metastases will develop bone metastases, an extremely painful condition.
Q BioMed Inc. (QBIO) and ASDERA LLC today announce a licensing agreement that provides Q Biomed with the worldwide exclusive rights to ASDERA's ASD-002, which is being developed to treat a rare pediatric nonverbal disorder. Under the terms of the agreement, Q Biomed receives global rights to develop and commercialize the drug in the rare pediatric disease market. Among the more than 60,000 US children who develop autism spectrum disorders (ASD) every year, 20,000 become nonverbal or lose the ability to speak.
Q BioMed Inc. (QBIO), a biotechnology acceleration company is pleased to announce the appointment of Dr. Amy Ripka and Dr. Rick Panicucci, to its board of scientific advisors. Dr. Amy Ripka is the Executive Director of Medicinal Chemistry at WuXi AppTec.
Q BioMed Inc. (QBIO) has closed on its final tranche of the $4,000,000 funding announced on November 30th, 2016. SR89 is indicated for bone pain palliation, providing long-lasting relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. Last week, Q BioMed management attended the 2017 OMRF BioVenture Forum, an industry event organized and hosted by the Oklahoma Medical Research Foundation (OMRF), where we advanced discussions on the development of a novel liver cancer drug candidate.
Q BioMed Inc. (QBIO), has closed on its 2nd tranche of the $4,000,000 funding announced on November 30th 2016. The drug, generic Strontium Chloride 89 injection, provides long-lasting relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage breast, prostate or lung cancer. There are approximately 350,000 cases of patients living with bone metastases in the U.S. alone.
Q BioMed, Inc. (QBIO) has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. The technology will utilize "uttroside B" and the compound's derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer was recently demonstrated in a November 3, 2016 study published in Scientific Reports, a Nature journal.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that Mannin Research, its research partner for the development of a novel pharmaceutical eye-drop to treat Primary Open-Angle Glaucoma utilizing the Tie2 Mechanism of Action, has been accepted into Johnson & Johnson Innovation, JLABS @ Toronto. Q BioMed focuses on acquiring companies and biomedical assets, providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, and enabling them to provide products to patients in need.